Acurx Pharmaceuticals, Inc.

Equities

Delayed Nasdaq Other stock markets 03:38:38 2026-05-19 pm EDT			5-day change	1st Jan Change
1.890 ^USD	+5.00%		-7.80%	-24.10%

May. 12	Acurx Pharmaceuticals, Inc., Q1 2026 Earnings Call, May 12, 2026
May. 11	Acurx Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Published on 11/12/2025 at 10:20 am EST

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Greetings, and welcome to the Acurx Pharmaceuticals Third Quarter 2025 Conference Call and Business Update.

[Operator

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

May. 12	Acurx Pharmaceuticals, Inc., Q1 2026 Earnings Call, May 12, 2026
May. 11	Acurx Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
May. 04	Acurx Pharmaceuticals, Inc. Presents Scientific Poster on DNA Pol IIIC Inhibitors' Microbiome Evaluation at ESCMID Global	CI
Apr. 26	Acurx Pharmaceuticals, Inc., Adiso Therapeutics, Inc., Summit Therapeutics Inc., Finch Therapeutics Group, Inc. and Astrazeneca plc Announces Clostridium Difficile Infections Clinical Trial Updates	CI
Apr. 20	Acurx Pharmaceuticals to discuss first quarter 2026 financial results on May 12, 2026 conference call and provide business update	RE
Apr. 16	Acurx Pharmaceuticals, Inc. announces closing of up to $7.1 million registered direct offering priced at-the-market under Nasdaq rules	RE
Mar. 30	Acurx Pharmaceuticals Inc Grants New Patent for Dna Polymerase Iiic Inhibitors	CI
Mar. 24	Top Premarket Gainers	MT
Mar. 13	Acurx Pharmaceuticals, Inc., Q4 2025 Earnings Call, Mar 13, 2026
Mar. 12	Acurx Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Mar. 12	Top Premarket Decliners	MT
Mar. 11	Acurx Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	CI
Mar. 09	Acurx Pharmaceuticals Inc Announces New Ibezapolstat Clinical Trial Program In Patients With Recurrent CDI	CI
Nov. 12	Acurx Pharmaceuticals, Inc., Q3 2025 Earnings Call, Nov 12, 2025
Nov. 12	Acurx Pharma Q3 net loss narrows to $2 mln	RE